Better Buy in 2026: Pfizer or Eli Lilly?
Eli Lilly has been a dominant force in the GLP-1 market, and that looks set to continue. Pfizer’s…
My Top 3 Healthcare Stocks to Buy in 2026
With its diverse product line, AbbVie is a terrific dividend stock with a solid underlying business. Eli Lilly…
Oh no, Ozempic! Eli Lilly’s New Weight-Loss Drug KOs Rival Treatments
How do you swear in Danish? Our AI chatbots are much too polite to help us out here,…
Do These 3 Healthcare Stocks Need a Checkup?
Pfizer has a sizable 6.8% yield and is down nearly 60% from its 2021 highs. Bristol Myers Squibb…
Eli Lilly Trims Price of Popular Weight-Loss Drug on Its Site a Month After Trump Deal
Shelby Knowles / Bloomberg / Getty Images Eli Lilly shares have added over a third of their value…
Lilly cuts price for obesity drug Zepbound
Trump announces lower prices coming for GLP-1 drugs Zepbound, Wegovy President Donald Trump announces discounted pricing for Zepbound…
Ozempic Prices Lowered After Trump Deal
Topline Novo Nordisk on Monday lowered the direct-to-consumer prices of its weight loss drug Wegovy and diabetes treatment…
Novo cuts Wegovy prices, Zepbound cost also coming down
Novo Nordisk is chopping prices again for Wegovy, but doctors say the expense will remain challenging for patients…
Eli Lilly and Novo Nordisk May Soon Sell Weight Loss Drugs on the Planned TrumpRx. Could This Further Boost the Healthcare Giants’ Stocks?
Don’t look now, but the costs of America’s beloved weight loss drugs are about to come down. Way…
Mangoceuticals Partners with Eli Lilly and Novo Nordisk to Deliver Affordable Access to Zepbound and Wegovy for Obesity Management
Mangoceuticals, Inc. Dallas, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) — Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”),…
Eli Lilly, Tan France launch Zepbound ‘Changing the Thread’
New innovative campaign weaves science and storytelling to help reframe obesity as a chronic disease INDIANAPOLIS, Nov. 10,…
Mounjaro mounts to top spot in Indian drug market; Oct sales touch ₹100 cr, ETPharma
New Delhi: Maintaining its growth momentum for the seventh straight month, Eli Lilly’s type-2 diabetes and weight-loss drug…